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Abstract 
Monoclonal antibody-based immunotherapeutics will dominate Pharma’s next generation of 
blockbuster drugs, and Fc-associated functions, including antibody dependent cellular 
cytotoxicity (ADCC) are among the highly desired activities mediated by these antibodies. 
Therefore, quantitative evaluation of ADCC is required during drug development. 
Our objective was to find the most suitable and reliable non-radioactive method for quantitative 
analysis of in vitro ADCC against adherent cells, which often serve as models for solid tumors. 
The test system was comprised the HER2 positive JIMT-1 cells targeted by the specific 
therapeutic antibodies trastuzumab (Herceptin
®
) and pertuzumab (Perjeta
®
). These cells are 
resistant to the direct biological effects of these antibodies, and therefore allow the isolated 
assessment of ADCC.  
We compared fluorescein diacetate (FDA) and carboxyfluorescein diacetate succinimidyl ester 
(CFSE) release as a fluorescent alternative to 
51
Cr release; propidium iodide (PI) uptake revealing 
increased membrane permeability; the PanToxiLux assay measuring ADCC induced pro-
apoptotic protease activity in flow cytometry; and an impedance-based real time cell adhesion 
test.  
We found that release assays are compromised by high spontaneous release of the label. PI 
uptake could not differentiate well between spontaneous NK activity and specific ADCC. The 
PanToxiLux assay, besides allowing for shorter assay times, offers improvement over the 
previous approaches in distinguishing spontaneous and antibody mediated NK action, but, 
probably owed to the prolonged detached state of adherent target cells, only at highly saturating 
antibody concentrations.  
In the case of adherent target cells, impedance-based cell analysis attains functional information 
exclusively on the target cells without having to label them for distinguishing from effectors or 
assay readout. It also allows continuous monitoring for days, and specifically detects target cell 
detachment, as the final functional consequence of ADCC. The sensitivity of this method even 
allows for quantitating the additivity and saturability of ADCC as a function of antibody 
concentration. 
We conclude that impedance-based assays are the most sensitive for quantitatively assessing in 
vitro ADCC on adherent target cells. 
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Introduction: 
Immunotherapy of cancer and other diseases has become one of the most promising and popular 
research areas in medicine (1). One focus of these therapeutic approaches is how we can modify 
or improve the patient’s cellular immune system to cope with a specific disease.  
 
Monoclonal antibody-based immunotherapeutics will dominate Pharma’s next generation of 
blockbuster drugs (2). The evaluation of the biological activity of mAbs is required during most 
drug development (3), and the European Medicines Agency and the U.S. Food and Drug 
Administration have each drafted guidelines (4,5) for the development of biosimilar products; 
extensive structural and functional characterization of the proposed product is recommended. 
 
When antibody therapy using humanized monoclonal antibodies against tumors was first coined, 
parent antibodies were selected based on their in vitro antitumor effect. Consecutively, it became 
apparent that in addition to direct cell biological effects, antibody dependent cell-mediated 
cytotoxicity (ADCC), and other Fc fragment-associated functions such as complement-dependent 
cytotoxicity (CDC) and complement activation are equally, if not more important in the 
antitumor therapeutic effect of these antibodies, when applied in the clinical setting.   
 
Thus, one important scenario is the quantitative assessment of the ADCC-promoting ability of 
newly developed therapeutic antibodies. The other emphatic area is the use of antibody 
combinations, where additive, synergistic, or antagonistic interactions need to be explored 
quantitatively.  
 
The objective of the present study was to find the most suitable and reliable non-radioactive 
method for quantitative analysis of in vitro antibody-dependent cellular cytotoxicity (ADCC) 
against adherent target cells, which often serve as models for solid tumors. Therefore, the 
51
Cr 
release assay was not included in the comparison. While this latter was originally regarded as 
reproducible and easy-to-perform, several of its drawbacks have been revealed lately. It turned 
out that it is semi-quantitative, only moderately sensitive, prone to poor labeling, and there is 
high spontaneous release from some target cell lines (6). In addition, the 
51
Cr release assay raises 
the obvious biohazard and disposal issues, and all these contraindications have led to attempts for 
its replacement with non-radioactive assays (6-8). 
 
Herein, we evaluate several non-radioactive assays with two particular therapeutic antibodies  
targeting the HER2 oncoprotein. The overexpression of this cell surface protein can be 
demonstrated in many tumor types, and correlates with poor clinical outcome. Trastuzumab 
(Herceptin
®
) and pertuzumab (Perjeta
®
) are both humanized monoclonal antibodies in clinical 
use (9,10) targeting distinct extracellular regions of HER2 (11,12). Their mechanisms of action 
include direct biological effects as well (13), but antibody-dependent cellular cytotoxicity 
(ADCC) appears to be of the greatest clinical relevance (3,14-16), and recently it was established 
that antibody doses exceeding the highest approved clinical doses do not saturate the ADCC 
response (14). This emphasizes the need for quantitatively analyzing the dose dependence of 
ADCC for antibodies under development or evaluation. 
 
As target system, we have chosen the JIMT-1, a HER2-positive human breast cancer cell line, 
established from pleural metastasis (17). JIMT-1 cells, even though they express the target HER2 
molecule, have proved to be in vitro resistant to the direct cell biological effects of both 
trastuzumab and pertuzumab. However, both in vitro, and when freshly inoculated into SCID 
mice, JIMT-1 tumors are sensitive to ADCC mediated by these antibodies (3,14-16). Therefore, 
their use allows the isolated observation and quantification of ADCC without being disturbed by 
the direct biological effects of these antibodies. 
 
The principle driving the choice of ADCC assays to be evaluated was to choose at least one assay 
from each major group of widely applied assays, and to choose the most frequently suggested 
ones when such could be identified. So we set out to analyze the following groups. 
(a) Since ADCC imposes the damage of target cell membrane, assays quantitating the release of a 
preloaded or native substance upon damage are the abundant. Of these, we have tested the 
applicability of fluorescein diacetate (FDA) as well as of carboxyfluorescein diacetate 
succinimidyl ester (CFSE). (b) The complementary assay to release-based methods are uptake-
based ones. Of these, measurement of propidium iodide (PI) uptake is a gold standard for 
assessing increased membrane permeability during cell death. We have tested this method, 
supplemented with CFSE labeling of the target cells to differentiate them from effector cells. (c) 
Since ADCC induces the activation of caspases by depositing active granzyme B into the target 
cells (18), a group of assays testing the activity of these enzymes in target cells using specific 
substrates has recently gained grounds (19). Of these, have chosen the PanToxiLux assay 
(OncoImmunin) that can be supplemented with the fluorescent identification of target vs. effector 
cells and the exclusion of target cells that are dead or dying before adding the effector cells (20). 
(d) Complex impedance variations caused by cells attached to electrodes can be related to cell 
coverage, establishment of cell-to-cell junctions, and cell–substrate interactions (21), thus being 
useful in proliferation, viability and spreading (22), wound healing (23) and cytotoxicity (24-27) 
assays. Thus, we have chosen to evaluate impedance-based  cell analysis as well, since it is 
inherently suitable for quantitating ADCC induced cell death in adherent cultures, which often 
serve as models for solid tumors. 
 
 
Materials and Methods 
 
All reagents were purchased from Sigma-Aldrich (Budapest, Hungary) unless otherwise 
indicated. 
 
Cell lines: 
Target cells: JIMT-1 cells were cultured in 1:1 ratio of Ham’s F-12 (N6760) and DMEM 
supplemented with 20% FCS, 300 U/L insulin (I9278), glutamine and antibiotics and split every 
3-4 days. 
Effector cells: the CD16.176V.NK-92 cell line, here abbreviated NK (from Dr. Kerry S. 
Campbell, the Fox Chase Cancer Center, Philadelphia, PA) was used. The cell line was derived 
from a human NK-like phenotype non-Hodgkin’s lymphoma (28), and has been transduced to 
express a high affinity variant (176V) of the FcγRIIIA receptor (CD16) (29,30). The cell line was 
cultured in special NK medium: α-MEM containing 10% FCS and 10% horse serum (Hyclone), 
supplemented with glutamine, non-essential amino acids, Na-pyruvate, antibiotics and IL-2 at 
100 IU/ml (Proleukin, Novartis).  
All cell cultures were maintained at 37 °C in a humidified atmosphere containing 5% CO2 and 
were routinely checked for the absence of mycoplasma contamination. 
 
FDA and CFSE labeling 
Being actively converted by living cells into the green fluorescent compound fluorescein, FDA is 
routinely used in the assessment cell viability. Carboxyfluorescein diacetate succinimidyl ester 
(CFSE) is also a cell-permeant, fluorescein-based tracer, which is retained in the living cell not 
only by its polar nature, but also by covalent attachment to proteins, thus allowing longer term 
labeling than CDA. For release assays using these two tracers, freshly detached JIMT-1 cells 
were suspended in sterile PBS at 1 million cells/ml and labeled with 10 µg/ml FDA, or 10 µg/ml 
CFSE (mixed isomers, ThermoFisher Scientific) for 30 minutes at 37°C. Cells were washed 3 
times with indicator free DMEM at 37°C for 1, 5 and 10 mins for cell number calibration and 10, 
20 and 30 mins for flow cytometric ADCC experiments. 
For assessing the time course of spontaneous release, JIMT-1 cells were seeded in 24-well plates, 
at 100,000 cells/well. 24 hours later cells were labeled with FDA or CFSE at 10 µg/ml 
concentration in sterile PBS for 30 mins at 37°C, followed by washing three times with indicator 
free DMEM.  
 
FDA and CFSE spontaneous release assays 
For examining spontaneous dye release as a function of cell number, labeled JIMT-1 cells were 
seeded in 96-well plates at numbers indicated in 200 µl indicator free DMEM. Cells were 
incubated for 24 hours at 37°C, then a 100 µl sample was taken from each well after gentle 
mixing of the medium and placed into wells of another 96-well plate for fluorescence 
measurement.  
To assess the amount of remaining dye, the medium was changed on the cells and cells were 
lysed with 0.1% Triton X-100. 
For assessing the time course of spontaneous release, after labeling and washing of JIMT-1 cells 
attached in 24-well plates (100,000 cells/well), 1 ml indicator free DMEM was placed on the 
cells. 100 µl samples from supernatant were taken from each well at given time points and placed 
in wells of a 96-well plate for fluorescence measurement. Consecutive readings were corrected 
for the cumulative loss of volume owed to previous samplings. 
Fluorescence was read out with a Synergy HT Multi-Detection Microplate Reader, (Bio-Tek, 
Winooski, VT, USA), with optics at the bottom using 485/20 nm excitation and 538/20 nm 
emission filters, and sensitivity set to 50. Fluorescence intensity was background corrected by 
subtracting that of the unlabeled medium.  
 
Flow cytometric ADCC assay based on PI uptake 
PI reveals cell death due to increased membrane permeability. To distinguish targets from 
effectors, freshly detached JIMT-1 cells were labeled with CFSE as described above, suspended 
in indicator free DMEM, and 100,000 cells in 200 µl were placed in sorter tubes. 200,000 NK 
cells suspended in 300 µl NK medium (without IL-2 to prevent general non-specific activation) 
were added to the target cells. Trastuzumab was added at 10 µg/ml final concentration where 
indicated. During incubation at 37°C, samples were protected from light. 100 to 200 µl samples 
were taken from each tube at given time points for up to 5 hours. PI was added to the samples 5 
minutes before measurement at a final concentration of 5 µg/ml. Flow cytometry measurements 
were performed on a BD FACSCalibur flow cytometer; 20,000 events were collected. Both 
CFSE and PI were excited with a 488 nm laser, CFSE signal detected in the FL1 (530/30), and PI 
in the FL3 (670LP) channel to minimize spillage of the CFSE signal into the PI signal and thus 
obviate the need for compensation. Data analysis was performed with FCS Express 4 (De Novo 
Software, Glendale, CA, USA).  
 
Fluorogenic ADCC assay specific for apoptosis using the PanToxiLux kit 
Fluorogenic ADCC assay kits aim to detect lethal hits long before target cells disappear owed to 
fragmentation. By lethal hit we understand any complex process initiated by the immune cell that 
eventually will lead to the death of the target cell. Granzyme B is a major component of the 
granules of cytotoxic lymphocytes and has received the most attention as a cytotoxic mediator 
because its protease activity is quite similar to caspases (18). Although no granzyme B activity is 
measurable in CTL or NK effector cells, this activity rapidly becomes detectable throughout the 
cytoplasm of the target cell after effector-target engagement. Detection of granzyme B and 
caspase 3 activity in the target cells can provide a unique readout of a potentially lethal injury 
delivered by cytotoxic immune cells (31). We have used the PanToxiLux
TM
 kit (OncoImmunin 
Inc., Gaithersburg, MD) to detect granzyme B and caspase activity in the target cells. Two 
additional intracellular dyes, NFL1 and TFL4 can be used in conjuction with the kit. The former 
labels cells that have died prior to the start of experiment and allows their exclusion from 
analysis, while the latter labels all target cells and can be used to discriminate target cells from 
effector cells. 
Target cells were suspended in PBS containing NFL1 and TFL4 intracellular dyes, incubated for 
30 mins at 37°C and washed twice, according to product manual. Coincubation of target and 
effector cells was done according to product manual in 50 µl PanToxiLux substrate containing 
the ADCC-mediating antibodies at given concentrations and incubated for 40 mins at 37°C. 
30,000 events from each sample resuspended in 200 µl wash buffer were measured with a BD 
FACS Aria III, with excitation and emission set as follows: NFL1 (ex: 405 nm, em: 450/20), 
TFL4 (ex: 633 nm, em: 660/20), PanToxiLux substrate (ex: 445 nm, em: 530/30). Gating strategy 
is provided as a supplementary figure along with MIFlowCyt specifications. 
 
Impedance-based real-time cell analyzer 
The ECIS Zθ impedance-based cell analyzer system from Applied Bioscience (Troy, NY) 
measures simultaneously complex impedance spectra (Z, R, C) of adherent cells growing in wells 
on gold electrodes over a broad range of AC frequencies between 62.5 Hz to 64000 Hz. The 
measured impedance depends on ionic concentration in the well and whether cells are attached to 
the electrodes. Cells attached to the electrodes will act as insulators and thereby alter the local 
ionic environment at the electrode/solution interface, leading to an increase in impedance. It is a 
non-invasive instrument capable of monitoring cell behavior in real-time without the use of 
labels. 
JIMT-1 cells were seeded in 8-well chambers (Ibidi, 8W10E) in JIMT-1 medium, at a 
concentration of 100,000 cells/well that provides a confluent cell layer on the electrodes after 
spreading (24 hours). Effector/target ratio was set at 2.5:1, NK effector cells and/or antibodies at 
defined concentration were administered in NK medium after impedance of the target cells has 
reached plateau (24 hours). Wells that did not receive NK cells as treatment were also 
administered the same volume of cell-free NK medium. The impedance spectrum of cells 
adhered to the electrodes assessed was measured ~ every 3 minutes in each well. The resistive 
component of impedance at 4000 Hz showed the greatest sensitivity and was chosen for further 
analysis. Impedance values were normalized to the value of the same well measured at the start of 
treatment. The plates and the measuring device was kept in a 5% CO2 humidified incubator at 
37°C. Plates were only briefly removed from the incubator to administer treatment.  
 
Statistical evaluation of data 
Experimental data are presented as means ± SD or SEM as indicated at the figures. Statistical 
analysis was performed using GraphPad Prism (version 7.0). To analyze the effect of ADCC, 
survival of the target cells in various treatments was compared using one-way ANOVA followed 
by Tukey’s multiple comparison test at α=0.05.  
  
Results and Discussion 
 
FDA and CFSE labels suffer spontaneous release which can confound specific ADCC 
dependent release 
 
In ADCC assays, it is indispensable to discriminate target cells from effector cells. Labeling all 
living target cells with FDA or CFSE prior to mixing them with NK cells serves this purpose 
well. Importantly, the same label released from the target cells by cytolysis during ADCC can be 
quantitated in the supernatant.  
 
Given the time needed to implement ADCC resulting in measurable membrane damage, first we 
tested the spontaneous release of the label from the target cells. The supernatant contained a well 
detectable amount of fluorescent dye due to spontaneous release (Figure 1a), which correlated 
with the number of cells releasing the dye. This is problematic, since this spontaneous release can 
interfere with the reliable estimation of release owed to ADCC-based cell lysis.  
 
CFSE is expected to be better retained within the cells as it covalently binds to cellular proteins. 
We found that the supernatant of CFSE-labeled cells showed lower fluorescent intensity than that 
of the FDA stained (Figure 1a), but this spontaneous release could still be the cause of concern. 
 
To examine the dynamics of spontaneous release, its time dependence was measured as well 
(Figure 1b). FDA and CFSE release showed a saturation curve as a function of time, reaching the 
endpoint of the release after 2 and 3 hours, respectively. By 24 hours, no further label could be 
released from the cells (Figure 1c): fluorescence in the freshly changed medium was not 
significantly increased during a four-hour follow up period. Consecutive lysis of the cells with 
0.1% Triton X-100 releasing all remaining intracellular fluorescent staining caused some increase 
in the case of CFSE labeled cells but no increase with FDA labeled cells. This supports the 
expectation that CFSE is retained better and for a longer period in the cell, but the absolute 
amount of the retained fluorescent dye that can be released by lysis is negligible, only ~5%  of 
the amount released spontaneously over the first 4 hours. This does not provide sufficient signal 
for detecting minute changes, and, importantly, the consequent ADCC reading would also be 
confounded with continuing spontaneous release. 
 
Regarding the FDA and CFSE release assays, we can conclude that the rate and timing of 
spontaneous release does not allow the quantitation of dye release caused specifically by ADCC, 
which occurs on the same time scale. Therefore this assay has not been further analyzed in terms 
of quantitative performance. 
 
PI uptake combined with CFSE as a target cell marker detects decreased cell viability, but 
cannot differentiate between background NK activity and specific ADCC 
 
In spite of spontaneous release, the intracellular fluorescence of the more stable CFSE label still 
can be sufficient for discriminating labeled target cells from non-labeled effector cells by flow 
cytometry even 4 hours after labeling. In fact, detection and quantification of dead and live 
CFSE-labeled target cells using flow cytometry was shown to be more sensitive than release 
assays (6). The spectral separation also allows the separate observation of PI uptake by target 
cells with damaged cell membrane. The lowest spectral overlap was attained by using the FL1 
and FL3 channels for CFSE and PI, respectively. After gating for intact cells in the FSC-SSC dot 
plot, CFSE signal discriminating NK cells from JIMT-1 target cells and PI signal discriminating 
PI positive dead cells from PI negative live cells resulted in 4 subgroups clearly distinguishable 
from each other (Figure 2a). Survival ratio of target cells was calculated and normalized to that of 
NK treated samples of the same experiment. This method of normalization was used throughout 
for comparing the various assays. In this PI uptake assay, NK cells significantly decreased the 
survival of the JIMT-1 target cells compared to untreated control even without antibody. 
However, adding trastuzumab antibody did not cause further significant changes in survival. 
(Figure 2b).  
 
There can be at least two reasons why this method cannot distinguish between each of the 
control, NK only, and NK + Tr groups. On the one hand, PI positivity may not be specific 
enough; a temporary perturbation caused by NK cells could be reflected in a greater PI positive 
fraction of target cells than those that actually have suffered a lethal hit. On the other hand, since 
most cellular models from solid tumors (including the JIMT-1 cells) are adherent, their viability 
and sensitivity to NK cells could be different in the longer term (several hours) under suspension 
culture conditions.  
 
Thus, the conclusion about the PI/CFSE assay is that it is probably not specific enough and is 
heavily influenced by the adherent target cells having to be trypsinized. Therefore, in our next 
experiments, we have explored assays that are (a) more specific in quantitating lethal hits and (b) 
are also adapted to adherent cells in addition to being specific. 
 
Flow-cytometric measurement of caspase activity using PanToxiLux improves the 
specificity of detecting lethal hits in ADCC as compared to PI uptake  
In an attempt to improve the specific detection of lethal hits, the PanToxiLux kit was chosen as a 
representative of the methods that detect activated granzyme B and/or caspases. The additional 
TFL4 label on target cells proved to be as effective in discriminating them from NK cells as the 
CFSE staining, while NFL1 labeling allowed the discrimination of target cells that were already 
dead before ADCC started (Supplementary Figure for MIFlowCyt). NK cells even without the 
antibody significantly (p = 0.013) increased the proportion of lethal hits compared to control, 
similarly to the PI-based test (p = 0.012, Table 1). In addition, the further increase in the ratio of 
lethal hits upon supplementing NK cells with the antibody was also significant (for 10 µg/ml 
trastuzumab, p < 0.0001 as opposed to p = 0.516 measured with PI, Table 1). 
However, we also learned that this ratio of lethal hits varies widely between experiments in 
coherence with the variation of background activity of NK cells. Only the sample treated with 
NK + 10 µg/ml trastuzumab showed a significant difference from the NK-only control, although 
some other high antibody doses were nearly significantly different as well (Figure 3). 
Trastuzumab F(ab’)2 served as control showing that in the absence of the Fc region no ADCC is 
mediated, so the extent of killing is similar to that of NK cells alone (Figure 3). 
 
We can conclude that measurements using the PanToxiLux kit allow to compare the potency of 
the two antibodies to mediate ADCC. Pertuzumab was less potent than trastuzumab, while their 
combination showed a similar effect to trastuzumab alone (Figure 3). However, the 
differentiating ability is decreased by the relatively large variability of data, which could be 
attributed to the prolonged suspension condition target cells are exposed to. It is reasonable to 
assume that detachment alone does not heavily influence viability, since PI-positivity of control 
JIMT-1 cells was ~10%. Rather, detachment influences NK-target interaction by altering both 
membrane and cytoskeletal organization of the target cells. This is supported by other 
measurements, where SK-BR-3 mammary carcinoma cells were added to the targets replacing the 
NK cells, and no significant change in cell death was seen. So, as a final step of our investigation, 
we set out to characterize ADCC with target cells that are kept adherent. 
 
Real-time, impedance-based cell adhesion assay is specific, and is able to reveal the 
stochiometry of ADCC against adherent target cells  
For a more robust evaluation of cell impedance data, all time traces were normalized to starting 
cell index at treatment, and then point by point to the NK-only treated control. Multiple traces 
from several independent experiments were then pooled (Figure 4a). Dose calibration of the 
antibodies has revealed that 1 µg/ml and 10 µg/ml used in the other assays were saturating the 
response and thus the range needed to assess dose-dependence is 1-10 ng/ml.  
Using the normalized end-point cell indices, we have compared all treatments with each other 
similarly to previous experiments (Figure 4b). All doses of NK + antibody treatments were 
significantly different from the NK-only control at p = 0.05 or lower. Differences between similar 
doses were not significant (p > 0.05), e.g. pertuzumab or trastuzumab at 1 ng/ml or their 
combination at 0.5 + 0.5 ng/ml doses caused a similar degree of ADCC. Furthermore, different 
antibody doses, such as 10 ng/ml trastuzumab or pertuzumab vs. 1 ng/ml of these antibodies, or 1 
ng/ml trastuzumab plus 1 ng/ml pertuzumab vs. 1 ng/ml of either of these antibodies, were 
statistically different from each other. Being able to distinguish such differences is a key element 
to any further ADCC experiment conducted for improving or developing antibodies and 
understanding the pharmacodynamics of ADCC. 
 
PI/CFSE, PanToxiLux and impedance based assays are all suitable for quantitating 
background NK cell activity 
To explore if the assays investigated differ in the measured NK background activity, we have 
normalized survival data of NK-only treated samples to that of the untreated samples of the same 
experiments (Figure 5) and pooled the results of all independent experiments (Table 1). 
Background NK cell cytotoxicity was identical (p ≥ 0.85) in all the three ADCC methods. This 
suggests that background NK cell activity is irrespective of specific molecular targets and can be 
quantitated by any mainstream in vitro ADCC assay. It also shows that averaging over many 
experiments cancels the variation among various NK cell populations. However, for a limited 
number of measurements, it is still better to normalize to the actual NK background activity of 
each batch. 
 
Concluding remarks 
 
Parallel to the increasing popularity of immunotherapy, there is a need for novel, commonly 
accepted and standardized experimental methods to fulfill the special requirement of the field. 
We need to quantitate as precisely as possible the complex actions of the immune system in vitro. 
It is also desirable to use safer, non-radioactive methods in these investigations. Here we have 
compared various non-radioactive strategies that are currently available. We have, however, 
omitted the technically highly complex kits that require proprietary technology and engineered 
cells (TAG-Lite Assay, ADCC Reporter Bioassay (2)).  
  
ADCC involves the interaction of targets and NK cells, so one primary challenge is to distinguish 
these during the measurements. In release assays (radioactive and non-radioactive), 
discrimination of target and effector cells is based on prior labeling of target cells with 
radioactive or fluorescent materials. Besides the possible effects of this prior labeling on cells, it 
is the high spontaneous release of these labels that hampers the sensitive and reproducible 
application of these methods. We have confirmed this for FDA as well as for the more stable 
CFSE labeling. Heterogeneity of labeling owing to the differential expression and activity of 
various ABC transporters in the target cell population could pose an additional problem. 
 
Regarding other popular release assays, the dissociation-enhanced lanthanide fluorescence 
immunoassay (DELFIA®) type time resolved fluorescence assays are not expected to be much 
different from FDA release in terms of premature/uncontrolled release of the label, even though 
they offer higher sensitivity. Another popular assay that is based on similar principles is the 
release of endogenous GAPDH, for which several commercial kits are available. However, it has 
already been shown that the proportional linear response of GAPDH assays is limited to small 
ranges of changes in viability and suffers from unsteady light output kinetics (32). These assays 
are also burdened with unpredictable influence by the actual metabolic state of the target cells, 
and can be confounded by GAPDH release from the effector cells. 
 
PI uptake, a frequently used indicator of cell death can have a formidable background, and is 
neither sensitive, nor specific to ADCC induced cell death. Fortunately, several other flow 
cytometry ADCC assays based on fluorescent substrates, such as PanToxiLux, offer an 
improvement over sensitivity and specificity, and decrease the amount of time needed to detect 
ADCC by detecting activated intracellular processes right at the start of ADCC. However, these 
assays are set up for flow cytometry, which carries disadvantages in the case of adherent target 
cells. Most cellular models from solid tumors are adherent, and it is not physiological for 
adherent cells to stay in suspension, as it can alter viability, sensitivity, and, importantly, the 
targetability of membrane molecules during ADCC. Fragmentation as a final outcome of cell 
killing and the simultaneous presence of spontaneous death of detached target cells can also 
influence assay outcomes.  
 
The use of label-free technologies based on electrical impedance is becoming more and more 
popular in drug discovery (33), since it allows the continuous monitoring of cellular processes, 
including attachment, spreading, proliferation, and cell death, including death by ADCC. This 
makes it possible to attain functional information exclusively on the target cells with no 
interference by the system used for detection, and minor changes owed to other components of 
the experimental system which can be corrected for by normalization.  
 
Thus, when using adherent target cells in ADCC, we advise the use of an impedance-based cell 
analyzer for several reasons: 
(a) adherent target cells may act differently if not attached to the surface. Targets may 
become more mobile upon detachment, or the antigen masking effect prevalent to 
adherent states and relevant to the clinical situation (34) can vanish. 
(b) impedance measurement does not alter target cells unlike loading with substrates 
(c) effector cells do not affect or alter the impedance readings 
(d) the assay is specific to the real, complete and functional effect on target cells, as the 
change in measured impedance is the result of cell detachment or utter change of 
morphology which can be regarded as the ultimate effect. 
(e) The extent and the time course of the evoked ADCC can easily be quantitated and 
different antibodies or antibody concentrations can be compared quantitatively. 
Consequently, this method was of great value for us in understanding the dose response 
function and stoichiometry of HER2 targeted antibodies alone and in combination (14). 
 
Overall, we can conclude that of the methods tested, impedance-based label free assays provide 
the greatest sensitivity in quantitating in vitro ADCC on adherent target cells. In addition to the 
ECIS Zθ, the xCELLigence Real-Time Cell Analysis Systems (ACEA Biosciences) could be an 
alternative for conducting such experiments. For non-adherent target cells, such as leukemia cell 
lines, impedance-based cell analyzers are not applicable, and assays detecting granzyme B and 
caspase activity in viable target cells are recommended. 
 
Finally, in terms of interpreting any ADCC data, we must emphasize that administering NK cells 
without any antibody already can have a notable effect on target cells. We consistently refer to 
this aspecific cytotoxicity as ‘background’ NK cell activity. Based on our experience, it is crucial 
to take this phenomenon into account in any type of assay by normalizing all specific treatments 
to the background activity of the very same set of effector cells. This makes it possible to pool 
independent experiments with highly different basal NK cell activities. 
 
 
Figure legends  
 
Figure 1. Fluorescence-based release assays 
a. Spontaneous release of the fluorescent label from FDA or CFSE labeled cells was tested 
in 96-well plates, with multiple cell densities. Supernatants were collected after 24 hours 
of incubation. Data points are averages ± SD from 4 independent experiments, each 
experiment run on 5 wells.  
b. Time course of spontaneous release was examined right after FDA or CFSE labeling and 
thorough washing of 100,000 JIMT-1 cells in 24-well plates. 100 µl samples were taken at 
specified time points from the wells. Data points are averages ± SD of 5 wells. 
c. Leftover fluorescent dye remaining in the cells was measured. 4 hours after FDA or CFSE 
labeling of JIMT-1 cells, supernatant was removed and renewed with fresh indicator free 
medium. Data points are averages ± SD of 5 wells. 
 
Figure 2. Flow cytometric ADCC assay with CFSE and propidium iodide 
a. Representative flow cytometric dot plot of JIMT-1 cells treated with NK cells (at 1:5 
ratio) + 10 µg/ml trastuzumab (Tr) for 5 hours. Effector cells can be distinguished from 
CFSE-labeled target cells based on the fluorescence intensity of CFSE in FL1. Propidium 
iodide positive cells are considered dead or dying cells.  
b. Survival rates of target cells after treatment are calculated from PI negative / PI positive 
CFSE labeled cells (± SD). Survival rate of each sample is normalized to survival rate of 
NK-only treatment. Samples are measured after 5 hours of treatment. *: p = 0.012 
***: p = 0.001, ns: p = 0.51).  
 
Figure 3. ADCC assay with PanToxiLux 
JIMT-1 cells were treated with NK cells + antibodies. 
a. Density plot from a PanToxiLux assay shows target JIMT-1 cells gated on the TFL4 
label. Substrate positive and negative cells are well separated in the upper quadrants. 
Antibody: 10 µg/ml trastuzumab. 
b. Survival ratio is calculated from PanToxiLux substrate negative and total target cells in 
each sample and normalized to that of the NK-only treated sample. Treatments are 
indicated in the figure. 7-11 independent experiments are averaged for each treatment (± 
SD). (***: p = 0.0005).  
 
Figure 4. ADCC assay with an impedance-based cell analyzer 
JIMT-1 cells were treated with NK cells (at 1:2.5 ratio) + 0.5-10 ng/ml trastuzumab and/or 
pertuzumab for 18 hours. 
a. The resistive component of the impedance was measured at 4000 Hz with an ECIS Zθ cell 
analyzer of attached JIMT-1 cells every 5 minutes. Treatment was administered after 
impedance reached plateau phase (in cc. 24 hours). Each trace is averaged for ≥ 2 
replicates per ≥ 3 independent experiments. The midline of the traces represents the mean, 
and the faded halo represents ± SEM. For a clearer view, some treatments are shown only 
in Figure 4b. 
b. The end-points of traces from Figure 4a are plotted (± SD). *: p ≤ 0.05; ****: p ≤ 0.0001 
 
Figure 5. Background (aspecific) cytotoxic activity of NK cells detected by different 
methods.  
Surviving fraction of target cells in NK-only treated samples was measured with PI/CFSE, 
PanToxiLux and impedance-based analysis, and normalized, for each assay modality, to survival 
measured for untreated (control) target cells. ns: p ≥ 0.87; n ≥ 8; 4-9 independent experiments, 
error bars indicate SD. 
 
Table 1. Statistical analysis of differences among major treatments measured with 
PI/CFSE, PanToxiLux and impedance-based assays 
The values in the table are the result of the statistical analysis of measured data presented in Figs. 
2, 3, and 4. One-way ANOVA followed by Tukey’s multiple comparison test was performed to 
analyze differences among three major treatments (untreated, NK-only, NK + Trastuzumab at 10 
µg/ml). Significant differences at p < 0.05 are marked bold.   
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Comparison CFSE/PI PanToxiLux Impedance 
Untreated vs. NK  0.012 0.013 0.196 
Untreated vs. NK+Tr 0.001 <0.0001 <0.0001 
NK vs. NK+Tr 0.516 <0.0001 <0.0001 
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